title: [Modern systemic therapy of advanced pancreatic cancer: impact on overall survival and medico economical aspects].
abstract: More than 75% of patients with advanced pancreas cancer present at a later stage, when only palliative chemotherapy can be offered as the main treatment. Since introduced, gemcitabine has significantly improved the symptomatic impact of the disease, and this single-agent therapy still remains the gold-standard treatment aside of any exploratory protocol. Survival benefits have however been marginal, although a minority of long-term survivors now survives their disease up to two or three years. Results from a retrospective study conducted on cases followed by the oncosurgery service of the Geneva University Hospital from 1993 to 2003 support this observation, and show a trend towards a parallel increase in ambulatory-incurred costs.
authors: Département de chirurgie, Oncochirurgie, HUG, 1211 Genève 14 mazzuri@hotmail.ch
authors: Sébastien
authors: S
authors: Mazzuri
authors: Arnaud
authors: A
authors: Roth
mesh_terms: D000328:Adult; D000368:Aged; D000553:Ambulatory Care / Q000191:economics*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007902:Length of Stay / Q000191:economics / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D012189:Retrospective Studies; D013557:Switzerland